Ketamine Not Yet Recruiting Phase 3 Trials for Sickle Cell Disorders Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02801292Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease